Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation

Transplantation

Volumn 94, Issue 4, 2012, Pages 396-402

  Schwarz, Anke ^a   Linnenweber Held, Silvia ^a   Heim, Albert ^a   Bröcker, Verena ^a   Rieck, Daniela ^a   Framke, Theodor ^a   Raggub, Lubna ^a   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

BK virus nephropathy; BK virus PCR; Polyomavirus; Renal graft failure; Renal transplantation

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ADULT; ARTICLE; BK VIRUS INFECTION; BK VIRUS NEPHROPATHY; CLINICAL ARTICLE; DELAYED DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS LOAD;

BK VIRUS; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 84865660986     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31825a505d     Document Type: Article

References (52)

1. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplantsVtubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324.
2. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488.
3. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
4. Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18: 1190.
5. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
6. Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834.
7. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 6(5 pt 1): 1025.
8. Khamash HA, Wadei HM, Mahale AS, et al. Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender. Kidney Int 2007; 71: 1302.
9. Weiss AS, Gralla J, Chan L, et al. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virusY associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 2008; 3: 1812.
10. Egli A, Kohli S, Dickenmann M, et al. Inhibition of polyomavirus BKYspecific T-Cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161.
11. Koukoulaki M, Grispou E, Pistolas D, et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis 2009; 11: 1.
12. Manitpisitkul W, Drachenberg C, Ramos E, et al. Maintenance im-munosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation 2009; 88: 83.
13. Prince O, Savic S, Dickenmann M, et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024.
14. Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010; 10: 407.
15. Tremolada S, Akan S, Otte J, et al. Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virusY associated nephropathy. Virology 2010; 404: 312.
16. Fishman JA. BK virus nephropathyYpolyomavirus adding insult to injury. N Engl J Med 2002; 347: 527.
17. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4: 2082.
18. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
19. Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85: 850.
20. Ramos E, Drachenberg CB, Wali R, et al. The decade of polyoma-virus BKYassociated nephropathy: state of affairs. Transplantation 2009; 87: 621.
21. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411.
22. Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosup-pression preserves allograft function in presumptive and definitive polyomavirus- associated nephropathy. Am J Transplant 10: 2615.
23. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokineticsof mycophenolic acid. Ther Drug Monit 2001; 23: 119.
24. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
25. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 2003; 22: 587.
26. Shaw LM, Nawrocki A, Korecka M, et al. Using established immu-nosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit 2004; 26: 347.
27. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistanceY associated protein 2. Am J Transplant 2005; 5: 987.
28. Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008; 86: 521.
29. Acott P, O'Regan PA, Crocker JF. Suppression of early and chronic BK polyoma virus replication by mycophenolic acid in Vero cells. Transpl Int 2009; 22: 225.
30. Buehrig CK, Lager DJ, Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64: 665.
31. Almeras C, Foulongne V, Garrigue V, et al. Does reduction in im-munosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008; 85: 1099.
32. Comoli P, Basso S, Azzi A, et al. Dendritic cells pulsed with poly-omavirus BK antigen induce ex vivo polyoma BK virusYspecific cy-totoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 3197.
33. Comoli P, Azzi A, Maccario R, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78: 1229.
34. Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006; 80: 3495.
35. Binggeli S, Egli A, Schaub S, et al. Polyomavirus BKYspecific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131.
36. Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of poly-omavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727.
37. Egli A, Helmersen DS, Taub K, et al. Renal failure five years after lung transplantation due to polyomavirus BKYassociated nephropathy. Am J Transplant 2010; 10: 2324.
38. Lipshutz GS, Flechner SM, Govani MV, et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4: 2132.
39. Wali RK, Drachenberg C, Hirsch HH, et al. BK virusYassociated ne-phropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004; 78: 1069.
40. Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virusYassociated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84: 83.
41. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21: 466.
42. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cyto-megalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84: 1436.
43. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490.
44. Liacini A, Seamone ME, Muruve DA, et al. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90: 1450.
45. Vigano M, Dengler T, Mattei MF, et al. Lower incidence of cyto-megalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 12: 23.
46. Sanchez Fructuoso AI, Calvo N, Perez-Flores I, et al. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transpl Infect Dis 2011; 13: 584.
47. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108.
48. Turner AP, Shaffer VO, Araki K, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8(+) T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011; 11: 613.
49. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517.
50. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin neph-rotoxicity in native kidneys of patients with glomerulonephritis. Nephrol Dial Transplant 2004; 19: 1288.
51. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allo-graft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67: 341.
52. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.